IL318931A - Multi-functional binding molecules - Google Patents
Multi-functional binding moleculesInfo
- Publication number
- IL318931A IL318931A IL318931A IL31893125A IL318931A IL 318931 A IL318931 A IL 318931A IL 318931 A IL318931 A IL 318931A IL 31893125 A IL31893125 A IL 31893125A IL 318931 A IL318931 A IL 318931A
- Authority
- IL
- Israel
- Prior art keywords
- binding molecules
- functional binding
- functional
- molecules
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263371861P | 2022-08-18 | 2022-08-18 | |
| PCT/EP2023/072802 WO2024038183A1 (en) | 2022-08-18 | 2023-08-18 | Multi-domain binding molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318931A true IL318931A (en) | 2025-04-01 |
Family
ID=87801079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318931A IL318931A (en) | 2022-08-18 | 2023-08-18 | Multi-functional binding molecules |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4573124A1 (en) |
| JP (1) | JP2025528212A (en) |
| KR (1) | KR20250051727A (en) |
| CN (1) | CN120077068A (en) |
| AU (1) | AU2023326804A1 (en) |
| CA (1) | CA3264964A1 (en) |
| IL (1) | IL318931A (en) |
| MX (1) | MX2025001959A (en) |
| TW (1) | TW202413410A (en) |
| WO (1) | WO2024038183A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026006492A2 (en) * | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anti-prame/hla-a2 antibodies and uses thereof |
| WO2026078231A1 (en) | 2024-10-11 | 2026-04-16 | T-Therapeutics Limited | Soluble non-aggregating immune ligand |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| WO1995018294A1 (en) | 1993-12-28 | 1995-07-06 | Komatsu Ltd. | Miller cycle engine |
| EP0977886A4 (en) | 1997-03-07 | 2002-10-23 | Sunol Molecular Corp | FUSION PROTEINS COMPRISING A COATING BACTERIOPHAGE PROTEIN AND A SINGLE CHAIN CELL RECEPTOR |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| BRPI9910332B8 (en) | 1998-05-06 | 2021-05-25 | Genentech Inc | method for purifying a polypeptide from a composition |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| PT1222292E (en) | 1999-10-04 | 2005-11-30 | Medicago Inc | METHOD FOR REGULATING THE TRANSCRIPTION OF EXOGENEOUS GENES IN THE PRESENCE OF NITROGEN |
| EP1259601A2 (en) | 2000-02-22 | 2002-11-27 | Ahuva Nissim | Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof |
| JP4336498B2 (en) | 2000-12-12 | 2009-09-30 | メディミューン,エルエルシー | Molecules with extended half-life and compositions and uses thereof |
| MXPA04001974A (en) | 2001-08-31 | 2004-07-16 | Avidex Ltd | Soluble t cell receptor. |
| NZ539225A (en) | 2002-10-09 | 2006-09-29 | Avidex Ltd | Single chain recombinant T cell receptors |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2502413A1 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| JP5563194B2 (en) | 2004-06-29 | 2014-07-30 | イムノコア リミテッド | Cells expressing modified T cell receptors |
| JP5794917B2 (en) | 2008-09-12 | 2015-10-14 | アイシス・イノベーション・リミテッドIsis Innovationlimited | PD-1-specific antibodies and uses thereof |
| CA2749558C (en) | 2008-12-08 | 2019-01-15 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| CN104105711B (en) * | 2012-02-10 | 2018-11-30 | 弗·哈夫曼-拉罗切有限公司 | Single-chain antibody and other heteromultimerics |
| WO2013164325A1 (en) * | 2012-05-02 | 2013-11-07 | F. Hoffmann-La Roche Ag | Multispecific antigen binding proteins |
| GB201522592D0 (en) | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| EP3408671B1 (en) * | 2016-01-25 | 2023-11-01 | F. Hoffmann-La Roche AG | Methods for assaying t-cell dependent bispecific antibodies |
| CA3011942A1 (en) * | 2016-02-03 | 2017-08-10 | Amgen Research (Munich) Gmbh | Psma and cd3 bispecific t cell engaging antibody constructs |
| MA44608B1 (en) | 2016-04-08 | 2022-06-30 | Immunocore Ltd | T cell receptors |
| AU2017305366B2 (en) | 2016-08-04 | 2019-06-20 | Innovent Biologics (Suzhou) Co., Ltd | Anti-PD-L1 nanobody and use thereof |
| GB201709866D0 (en) | 2017-06-20 | 2017-08-02 | Immunocore Ltd | T cell receptors |
| DE102017115966A1 (en) * | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptide molecule with improved dual specificity |
| IL272747B2 (en) * | 2017-11-01 | 2025-04-01 | Hoffmann La Roche | Bispecific 2 + 1 contorsbodies |
| GB201901306D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
| KR20220160598A (en) * | 2020-03-30 | 2022-12-06 | 고쿠리츠다이가쿠호진 미에다이가쿠 | bispecific antibody |
| US11976120B2 (en) * | 2020-06-01 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
-
2023
- 2023-08-18 IL IL318931A patent/IL318931A/en unknown
- 2023-08-18 KR KR1020257008721A patent/KR20250051727A/en active Pending
- 2023-08-18 CN CN202380073364.XA patent/CN120077068A/en active Pending
- 2023-08-18 EP EP23761095.1A patent/EP4573124A1/en active Pending
- 2023-08-18 CA CA3264964A patent/CA3264964A1/en active Pending
- 2023-08-18 WO PCT/EP2023/072802 patent/WO2024038183A1/en not_active Ceased
- 2023-08-18 TW TW112131156A patent/TW202413410A/en unknown
- 2023-08-18 AU AU2023326804A patent/AU2023326804A1/en active Pending
- 2023-08-18 JP JP2025508860A patent/JP2025528212A/en active Pending
-
2025
- 2025-02-17 MX MX2025001959A patent/MX2025001959A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250051727A (en) | 2025-04-17 |
| CA3264964A1 (en) | 2024-02-22 |
| JP2025528212A (en) | 2025-08-26 |
| WO2024038183A1 (en) | 2024-02-22 |
| TW202413410A (en) | 2024-04-01 |
| EP4573124A1 (en) | 2025-06-25 |
| CN120077068A (en) | 2025-05-30 |
| AU2023326804A1 (en) | 2025-03-06 |
| MX2025001959A (en) | 2025-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL315308A (en) | anti-frα binding molecules | |
| IL284926A (en) | CD3-specific binding molecules | |
| DK3645570T3 (en) | VISTA antigen binding molecules | |
| IL286013A (en) | cd3 binding molecules | |
| IL299630A (en) | Antigen binding molecules targeting SARS Cov2 | |
| EP3990428A4 (en) | NOVEL MOLECULES | |
| EP4522758A4 (en) | ABCA4 TRANSPLICATED MOLECULES | |
| IL299631A (en) | Antigen binding molecules targeting SARS Cov2 | |
| EP3774922A4 (en) | CELL-LINKING BINDING MOLECULES | |
| EP3976102A4 (en) | ANTI-GAL9 IMMUNE INHIBITOR BINDING MOLECULES | |
| IL316153A (en) | Molecules that bind TDP-43 | |
| IL288562A (en) | Activating gal9 binding molecules | |
| EP4352093A4 (en) | PROTEIN ANTIGEN BINDING MOLECULES | |
| EP4503392A4 (en) | Flux-concentrated motor | |
| PL3865551T3 (en) | BINDING COMPOSITION | |
| PL4172199T3 (en) | ALPHA-SYNUCLEIN PROTOFIBRILLI BINDING ANTIBODIES | |
| EP4467573A4 (en) | BISPECIFIC BINDING MOLECULE | |
| ES1294969Y (en) | Bookmark | |
| JP1731909S (en) | File | |
| JP1731907S (en) | File | |
| JP1731908S (en) | File | |
| JP1731901S (en) | File | |
| JP1731902S (en) | File | |
| JP1731903S (en) | File | |
| JP1731900S (en) | File |